In the largest group of 4053 participants of the Val-HeFT trial, the median hs-cTnT was 12.5 ng/L whereas it was only 4.4 ng/L in the cohort of the VitD-CHF trial and 28.0 ng/L in the study by Nakamura et al. [39] Although this heterogeneity can be explained by factors such as age, severity of HF, and co-morbidities [39], further studies may be needed to highlight the role of other factors, e.g., HF etiology including genetic determinants. The gene discussed is TNNT2; the disease is congestive heart failure.